Amicus Therapeutics Inc.

FoldRx Kicks Off Phase II/III Against Genetic Neuropathy.
BIOWORLD Today; 11/3/2009; 1162 words; ...experience, too. With Genome Therapeutics Corp. (now Oscient Pharmaceuticals...news lately include Biogen Idec Inc., of Cambridge, Mass., and...is Cranbury, N.J.-based Amicus Therapeutics Inc., which this spring - six months...

Biogen Idec Authorizes $3B Stock Buy-Back.
BIOWORLD Today; 11/3/2009; 1334 words; ...Tuesday, and Amgen Inc. authorized a...financing news: o Acorda Therapeutics Inc., of Hawthorne...Proceeds will support Amicus' Prolactis technology...Avalon Pharmaceuticals Inc., of Germantown...2007.) o Chemokine Therapeutics Corp., of Vancouver...

Clinic Roundup.
BIOWORLD Today; 11/3/2009; 840 words; o Affymax, Inc., of Palo Alto, Calif., initiated a clinical trial to evaluate...Phase II trials to treat anemia in patients with CKD and cancer. o Amicus Therapeutics, of Cranbury, N.J., said the Committee for Orphan Medicinal...

FoldRx Gets Up To $22M From Cystic Fibrosis Foundation.
BIOWORLD Today; 11/3/2009; 1186 words; ...770; Altus Pharmaceuticals Inc., which is in Phase III with ALTU-135; and PTC Therapeutics Inc., which is in Phase II with...working on protein misfolding is Amicus Therapeutics Inc., of Cranbury, N.J., which...

Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph., to Board of Directors.
PR Newswire; 11/3/2009; 642 words; ...FirstCall/ -- Amicus Therapeutics today announced...Merck & Co., Inc. John F. Crowley...President and CEO of Amicus Therapeutics stated, "Margie...invaluable to Amicus as we execute...Merck & Co., Inc. after more than...